J&J Advances Pipeline With Yondelis, Carisbamate Filings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures
You may also be interested in...
FDA To Centocor: Show Me The REMS
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
J&J Cautious On Paliperidone Palmitate
Could management’s lack of enthusiasm for the schizophrenia drug foreshadow a delay at FDA?